NCT07600177 Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy
| NCT ID | NCT07600177 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Oregon Health and Science University |
| Condition | Hypertrophic Cardiomyopathy (HCM) |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2026-05-05 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 40 participants in total. It began in 2026-05-05 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is an investigator-initiated two-center study. The goal of this study is to investigate the feasibility, safety and efficacy outcomes of a seamless transition from mavacamten to aficamten in patients with obstructive hypertrophic cardiomyopathy (oHCM).
Eligibility Criteria
Inclusion Criteria: * Documented history of oHCM with documented resting and/or Valsalva LVOT obstruction ≥ 50 mmHg who are currently receiving mavacamten commercially. * Echo-derived LVEF ≥55% on mavacamten at the time of enrollment. * Patient willing to consent for the study and undergo the study procedures. Exclusion Criteria: * Severe aortic stenosis or sub-aortic obstruction * Known infiltrative or storage disorder causing cardiac hypertrophy that mimics HCM (eg, Noonan syndrome, Fabry disease, amyloidosis). * History of LVEF \<30%. * Paroxysmal atrial fibrillation (AF) with documented episode within 3 months. * Atrial fibrillation (paroxysmal or permanent) not on systemic anticoagulation. * Documented history of current obstructive coronary artery disease (\> 70% stenosis in one or more epicardial coronary arteries) or documented history of myocardial infarction.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07600177 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 90 Years, studying Hypertrophic Cardiomyopathy (HCM). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07600177 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT07600177 currently recruiting?
Yes, NCT07600177 is actively recruiting participants. Contact the research team at masria@ohsu.edu for enrollment information.
Where is the NCT07600177 trial being conducted?
This trial is being conducted at Kansas City, United States, Portland, United States.
Who is sponsoring the NCT07600177 clinical trial?
NCT07600177 is sponsored by Oregon Health and Science University. The trial plans to enroll 40 participants.